CG Oncology (CGON) Liabilities and Shareholders Equity (2023 - 2026)

CG Oncology (CGON) has 4 years of Liabilities and Shareholders Equity data on file, last reported at $1.1 billion in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 55.9% year-over-year to $1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 billion (up 29.17% YoY) and the FY2025 annual result came in at $791.6 million, up 4.87% from the prior year.
• Liabilities and Shareholders Equity advanced to $1.1 billion in Q1 2026, from $791.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.1 billion in Q1 2026 to a low of $199.3 million in Q4 2023.
• A 4-year average of $673.6 million and a median of $714.8 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity soared 278.72% — and 2025, when it gained 4.87%.
• Tracing CGON's Liabilities and Shareholders Equity over 4 years: stood at $199.3 million in 2023, then soared by 278.72% to $754.8 million in 2024, then grew by 4.87% to $791.6 million in 2025, then jumped by 43.42% to $1.1 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.1 billion (Q1 2026), $791.6 million (Q4 2025), and $729.9 million (Q3 2025), per Business Quant data.